Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Emily McDonald
- Target Recruit Count
- 300
- Registration Number
- NCT06650501
- Locations
- 🇨🇦
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Abu Dhabi Health Services Company
- Target Recruit Count
- 67
- Registration Number
- NCT06606275
- Locations
- 🇦🇪
SEHA Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates
Secondary Prevention of VTE in Patients with Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 330
- Registration Number
- NCT06603870
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 212
- Registration Number
- NCT06515730
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1148
- Registration Number
- NCT06486792
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 32
- Registration Number
- NCT06474182
- Locations
- 🇫🇷
CHU de Saint-Etienne, Saint-Étienne, France
The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 324
- Registration Number
- NCT06449469
- Locations
- 🇩🇰
Aarhus University Hospital, Skejby, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
Thromboprophylaxis in Lower Limb Immobilisation
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 10044
- Registration Number
- NCT06370273
- Locations
- 🇬🇧
Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, United Kingdom
🇬🇧Barts Health NHS Trust, London, United Kingdom
🇬🇧Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3691397
- Registration Number
- NCT05838664
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13945
- Registration Number
- NCT05795062
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.